Gene therapy is finally poised to make a contribution to the treatment of debilitating, highly penetrant genetic diseases that have proved intractable to other regimens.
Testing kits delivered by courier and digital tools combine to battle the COVID-19 outbreak to find out which kits are most effective in protecting against infection.Expand
It is shown that people who self-identified as seekers of happiness through living a life of purpose have a gene expression profile favorable to the immune system, whereas hedonistic people, while claiming to be happy, had negative expression profiles.Expand
Drug developers are mounting a poly(ADPribose) polymerase (PARP) inhibitor comeback, and a few are now experimenting with a more comprehensive companion diagnostic to smooth the way, with more imminent competition to Imbruvica likely to come from newer, targeted agents in late-stage development, especially in CLL.Expand
A negative result would be a significant setback for the field, after the recent failures of two other anti-amyloid drugs, the gamma secretase inhibitor Flurizan and Alzhemed, which were designed to prevent beta amyloid aggregation.Expand
Although trebananib has definite biological effects, a precise understanding of its mechanism remains elusive, which may have led to its deployment in settings in which its performance was suboptimal, and could have a chilling effect on some drug developers investing in similar molecules.Expand
The first disease-modifying therapy for cystic fibrosis could reach the market next year, following the publication of highly promising data from two phase 3 trials in recent months, and marks the beginning of a new era of small-molecule drugs that could profoundly change the course of therapy for the vast majority of individuals with the disease.Expand
The catastrophic phase 1 clinical trial of German biotech TeGenero's monoclonal antibody designed to activate the immune system's T cells has raised serious concerns about the adequacy of the… Expand